Plaquenil in the Treatment of Discoid Lupus Erythematosus

Publisher Website
Google Scholar
Abstract
Despite adequately documented evidence of the effectiveness of the antimalarials quinacrine and chloroquine in the treatment of discoid lupus erythematosus,*a significant number of patients receiving these drugs derive little or no benefit from them, either because of side-effects of sufficient severity to compel discontinuance of medication, or simply because of lack of therapeutic effect. The desirability of a drug with greater therapeutic response, better tolerance, and less toxicity was evident, so when preliminary laboratory studies with Plaquenil † revealed such advantageous properties in malaria, clinical evaluation of this drug in the treatment of discoid lupus erythematosus seemed logical. DESCRIPTION OF THE DRUG Plaquenil or WIN 1258 (7-chloro-4-[4-(N-ethyl-N-β-hydroxyethylamino)-1-methylbutylamino]quinoline) is a 4-aminoquinoline similar to chloroquine but differs from the latter in that a hydroxyethyl group is substituted for one of the ethyl groups on the tertiary amino nitrogen

This publication has 0 references indexed in Scilit: